As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.

Stage 4 lymphoma is a blood cancer that has spread outside of the lymph nodes to other parts of the body. Learn the symptoms, ...

For low-risk patients with papillary thyroid carcinoma interested in something other than surgery or surveillance, ...

Dry eye disease metrics, such as NIBUT and MG dropout, may serve as predictive biomarkers for possible thyroid disorders.